Skip to content
The United States is the world leader in biotechnology, but the country wasn’t always on top, and there’s obviously no guarantee it will stay […]
BIO expert: China pushes WTO IP waiver to gain tech access Read More »
Clinical trial diversity is the cornerstone of equal access to care, but clinical trial participants are still overwhelmingly white. Data released by the Food
Clinical trial diversity is essential for equal access and good medicine Read More »
April marked the 10-year anniversary of the JOBS (Jumpstart Our Business Startups) Act. The bill, which was signed into law thanks to bipartisan support
Looking back on the JOBS Act, 10 years later Read More »
The opioid epidemic has hit the United States hard in the last 25 years, killing more than 70,000 in 2019 alone, according to the
FDA draft guidance on non-opioid analgesics ‘inadequate’ Read More »
This month’s decision by the U.S. Centers for Medicare & Medicaid Services (CMS) to limit coverage of the Alzheimer’s drug Aduhelm to patients enrolled in
Aduhelm decision will ‘chill’ innovation, say BIO experts Read More »
Bio.News interviewed Yvonne Greenstreet, who took the reins as CEO of Alnylam in January 2022, making her one of a small number of Black
Alnylam CEO Greenstreet: ‘You can go faster alone, but you go far together’ Read More »
Science helped save the world from COVID. What will vaccine technology do next? Today’s new episode of the I am BIO Podcast explores this
I am BIO Podcast: What will COVID vaccine technology do next? Read More »
The pandemic showed us that we can develop vaccines and other drugs in a short time, and get a lot of people vaccinated, but
POLITICO’s Health Care Summit: The Many Legacies of COVID Read More »
We need to use the lessons from the COVID-19 to improve our supply chain preparedness for the next pandemic, Phyllis Arthur, the Vice President
Watch: BIO’s Phyllis Arthur on supply chains and pandemic prep Read More »
A new federal research agency would seek solutions for the most challenging diseases, clinical trials would become more diverse, and patients would get new
The Cures 2.0 bill: ‘Frankly, patients can’t wait’ Read More »
